Scrip
US FDA warns Eisai for overstating efficacy of Dacogen in promotion
19 November 2009
Nancy Faigen
A promotional piece aimed at physicians and created by
Eisai "presents numerous claims that misleadingly overstate the efficacy" of the company's cancer drug Dacogen (decitabine), the
US FDA's division of drug marketing, advertising and communications (DDMAC) said in a warning letter to the company....
Please Login to read the full article.
19 November 2009
Nancy Faigen
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
